Olanzapine reduces chemotherapy induced nausea and vomiting compared to aprepitant in myeloma patients receiving high-dose melphalan prior to stem cell transplantation: A retrospective study
Chemotherapy induced nausea and vomiting (CINV) is common in patients who receive high-dose melphalan as conditioning regimen prior to autologous hematopoetic stem cell transplantation. With sub-optimal CINV control with an aprepitant based antiemetic regimen, we changed to an olanzapine based regimen. A retrospective study which compared these two regimens showed significant improvement in acute and delayed nausea control and reduction in CINV rescue medications.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Steven Trifilio, Colleen Welles, Kristin Seeger, Shivani Mehta, MaryAnne Fishman, Katherine McGowan, Kathryn Strejcek, Emily Eiten, Carolyn Pirotte, Elizabeth Lucier, Sean DeFrates, Jayesh Mehta Tags: Original Study Source Type: research
More News: Acute Leukemia | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants | Zyprexa